Epkinly 48 mg/0.8 mL injection Images
Generic Name: epcoritamab
This medication has been identified as Epkinly 48 mg/0.8 mL injection. It is supplied by AbbVie Inc.
Epkinly is used in the treatment of Diffuse Large B-Cell Lymphoma; B-Cell Lymphoma; Follicular Lymphoma and belongs to the drug class bispecific T-cell engagers (BiTE). Epkinly 48 mg/0.8 mL injection is not a controlled substance under the Controlled Substances Act (CSA).
Images of medication
Epkinly
- Generic Name
- epcoritamab
- Strength
- 48 mg/0.8 mL injection
- Availability
- Prescription only
- Drug Class
- Bispecific T-cell engagers (BiTE)
- CSA Schedule
- Not a controlled drug
- Labeler / Supplier
- AbbVie Inc.
- National Drug Code (NDC)
- 82705-0010
See also:
Rituxan
Rituxan infusion is used to treat certain leukemias and lymphomas and some non-cancer conditions ...
Truxima
Truxima is used to treat non-Hodgkin's lymphoma, chronic lymphocytic leukemia, rheumatoid ...
Monjuvi
Monjuvi (tafasitamab-cxix) is used for the treatment of relapsed or refractory diffuse large B-cell ...
Breyanzi
Breyanzi is a CAR T cell therapy for large B-cell lymphoma, CLL/SLL, follicular lymphoma, mantle ...
Kymriah
Kymriah is used to treat acute lymphoblastic leukemia (ALL) that is relapsing or refractory in ...
Polivy
Polivy (polatuzumab vedotin-piiq) is a targeted treatment that may be used to treat diffuse large ...
Yescarta
Yescarta is used to treat large B-cell lymphoma and follicular lymphoma, two types of non-Hodgkin ...
Xpovio
Xpovio is used to treat multiple myeloma (MM) or relapsed/refractory diffuse large B-cell lymphoma ...
Zynlonta
Zynlonta (loncastuximab tesirine) is used to treat relapsed or refractory diffuse large B-cell ...
More about Epkinly (epcoritamab)
- Check interactions
- Compare alternatives
- Pricing & coupons
- Drug images
- Side effects
- Dosage information
- During pregnancy
- FDA approval history
- Drug class: bispecific T-cell engagers (BiTE)
- Breastfeeding
- En español
Patient resources
Professional resources
Related treatment guides
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.